Jason Haas - Nov 18, 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Financial Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Nov 18, 2024
Transactions value $: -$28,980
Form type: 4
Date filed: 11/20/2024, 05:00 PM
Previous filing: Nov 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Sale	-$29K	-138K	-100%	$0.21^*	0	Nov 18, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.